I thought I would share an amazing "small world" experience tonight. I was invited to dinner in the home tonight of my Physician host for a talk I am giving in a Northern European country. In talking with his wife, a scientist specializing in omega-3's and oxidative stress and the possible role of fish oil in reducing inflammation, I happened to mention AMRN's ongoing R-IT trial with high dose pure EPA for reducing CV disease risk. She said she was well aware of it and that she had worked as lead scientist for a pharma competitor with a combo EPA/DHA drug that lost a patent suit to AMRN (after which the company closed down that line of research and she lost her job). After further discussion, as an omega-3 expert, she opined that it is highly likely that the R-I trial with pure EPA will succeed (despite her losing her job due to the AMRN patent victory). She stated that the high purity and high dose (4 gram) of V were key for efficacy in her view. This unplanned conversation tells me that scientists at competitor organizations have high certaintly about positive R-I results. I though this information I serendipitously learned was quite positive for eventual R-I outcomes.
Market Data 
Markets 
AI
